Clinical trials: Urinary Incontinence, Urge
Overactive Bladder Syndrome, Urinary Incontinence, Urge
Effectiveness of Bilateral PTNS Compared to Unilateral PTNS for the Treatment of Overactive Bladder/Urge Incontinence
This study is designed to evaluate whether bilateral Posterior Tibial Nerve Stimulation is more effective than unilateral Posterior Tibial Nerve Stimulation at treating overactive bladder and urge urinary incontinence
- Trial name
- BUTTON (NCT03535857)
- Testing
- PTNS
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- Gnankang Sarah Napoe
Overactive Bladder, Overactive Bladder Syndrome
Prophylactic Antibiotic Administration for Bladder OnabotulinumtoxinA Injection
The goal of this clinical trial is to evaluate the outcomes of differing durations of antibiotic prophylaxis with bladder onabotulinumtoxinA injection in patients with refractory overactive bladder.
- Conditions
- Overactive Bladder, Overactive Bladder Syndrome, Urge Incontinence, Urinary Incontinence, Urge
- Trial name
- NCT05719285
- Testing
- Single-Dose Antibiotic, Multi-Dose Antibiotic
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- The Cleveland Clinic
Urinary Incontinence
An Implantable Microstimulator for the Chronic Treatment of Refractory Urinary Urge Incontinence
This clinical trial is being conducted to investigate the safety and effectiveness of a new device designed to treat urinary urge incontinence in those patients who have tried and failed two or more conservative therapies.
- Trial name
- NCT00080470
- Testing
- bion
- Where
- 11 sites in United States
- Volunteers
- 148 people
- Sponsor
- Boston Scientific Corporation
Overactive Bladder
Sham Controlled Trial of Rapid Induction Percutaneous Tibial Nerve Stimulation
The aim of this study is to determine the efficacy of an accelerated course for percutaneous tibial nerve stimulation (PTNS) induction to treat overactive bladder symptoms.
- Trial name
- NCT03547518
- Testing
- PTNS treatment
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Corewell Health East
Pelvic Organ Prolapse, Urinary Incontinence,Stress
Minimally Invasive Burch Colposuspension to Reduce Occult Stress Incontinence
This study evaluates the addition of a laparoscopic Burch colposuspension procedure at the time of laparoscopic sacrocolpopexy to prevent stress urinary incontinence.
- Conditions
- Pelvic Organ Prolapse, Urinary Incontinence,Stress, Urinary Incontinence, Urge, Bowel Dysfunction
- Trial name
- MICRO (NCT03841513)
- Testing
- Laparoscopic Burch Colposuspension
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Northwestern University
Overactive Bladder, Urinary Urge Incontinence
InterStim Basic Evaluation Lead Post-Market Clinical Follow-up Study
Post-market clinical follow-up for continued assessment of safety and performance of the InterStim basic evaluation lead and foramen needle(s) used during a therapy evaluation.
- Conditions
- Overactive Bladder, Urinary Urge Incontinence, Urgency-frequency Syndrome
- Trial name
- BASIC (NCT04016324)
- Testing
- InterStim Basic Evaluation lead and foramen needle
- Where
- 15 sites in United States, Canada and 2 more
- Volunteers
- 110 people
- Sponsor
- MedtronicNeuro
Urgency Frequency, Urinary Urge Incontinence
InterStim Therapy Programming Study
This study assessed the effect of different InterStim rate settings on voiding diary outcomes. Specifically, the study evaluated how 3 different rate settings affected the number of urinary incontinent episodes per day collected…
- Trial name
- NCT01009333
- Testing
- InterStim Therapy at rate 5.2 Hz, InterStim Therapy at rate 14 Hz, InterStim Therapy
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- MedtronicNeuro
Overactive Bladder, Urinary Urge Incontinence
Over Active Bladder Instillation Study - Botox
The purpose of this study is to determine whether women with overactive bladder (OAB) who receive direct instillation via a catheter of a Botulinum-A Toxin (Botox) with Dimethyl Sulfoxide (DMSO) solution experience significantly…
- Conditions
- Overactive Bladder, Urinary Urge Incontinence, Urinary Incontinence, Detrusor Hyperreflexia
- Trial name
- NCT00667095
- Testing
- Botox Instillation, DMSO Instillation
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Mayo Clinic
Overactive Bladder
Overactive Bladder Innovative Therapy Trial (OrBIT)
The purpose of this study is to compare percutaneous tibial nerve stimulation (PTNS) to drug therapy for the treatment of symptoms of overactive bladder (OAB).
- Trial name
- OrBIT (NCT00448175)
- Testing
- Urgent PC Neuromodulation System, Tolterodine
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Uroplasty, Inc
Overactive Bladder, Urge Incontinence
Pivotal Study of eCoin for Overactive Bladder With Urgency Urinary Incontinence
This trial is a prospective, multicenter, single-arm study of the safety and effectiveness of eCoinTM tibial nerve stimulation in subjects having overactive bladder (OAB) with urgency urinary incontinence (UUI).
- Conditions
- Overactive Bladder, Urge Incontinence, Incontinence, Urinary, Urinary Urge Incontinence
- Trial name
- NCT03556891
- Testing
- eCoin Tibial Nerve Stimulation
- Where
- 15 sites in United States
- Volunteers
- 133 people
- Sponsor
- Valencia Technologies Corporation
Urinary Retention, Urinary Urge Incontinence
Axonics SacRal NeuromodulaTIon System RegisTRY Study
To assess the post-market clinical outcomes with use of the Axonics Sacral Neuromodulation System(s).
- Conditions
- Urinary Retention, Urinary Urge Incontinence, Urgency-Frequency, Fecal Incontinence
- Trial name
- ARTISTRY (NCT05064384)
- Where
- 27 sites in United States, Canada
- Volunteers
- 272 people
- Sponsor
- Axonics, Inc.
Urinary Incontinence
Enhancing Conservative Treatment for Urge Incontinence
The primary objective of this project is to evaluate whether enhancing drug therapy with components of behavioral training, including pelvic floor muscle rehabilitation, results in better outcomes than drug therapy alone for urge…
- Trial name
- COMBO (NCT00223821)
- Testing
- Oxybutynin chloride, extended-release, individually-titrated, Behavior Training
- Where
- United States
- Volunteers
- 166 people
- Sponsor
- US Department of Veterans Affairs
Urinary Bladder, Overactive
A Study to Compare the Effectiveness and Safety of Fesoterodine and Placebo in an Elderly Population of Patients Who go to the Toilet Very Frequently Due to Overactive Bladder.
The drug being studied, fesoterodine fumarate helps prevent the bladder neck opening at unwanted times and has been shown to help patients with overactive bladder syndrome pass urine less frequently than before treatment.
- Trial name
- SOFIA (NCT00798434)
- Testing
- Fesoterodine fumarate
- Where
- 60 sites in Austria, Belgium and 13 more
- Volunteers
- 794 people
- Sponsor
- Pfizer
Urge Incontinence, Urinary Incontinence, Urge
Treatment of Incontinence Without Memory Problems
An 8-week randomized, controlled, pilot clinical trial of Mirabegron compared to a standard anticholinergic therapy (Detrol LA) in elderly women with urgency urinary incontinence.
- Trial name
- TRIUMPH (NCT02436889)
- Testing
- Mirabegron, Tolterodine Tartrate
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Urinary Incontinence,Stress, Urinary Incontinence, Urge
RCT on Multimodal Self-treatment for Women With Incontinence Using a Digital Health Application
This study, titled "Prospective Randomized Study on Multimodal Self-Treatment for Women with Incontinence Symptoms Using a Digital Health Application," abbreviated as DINKS, aims to investigate the efficacy of a digital health…
- Conditions
- Urinary Incontinence,Stress, Urinary Incontinence, Urge, Urinary Incontinence, Overactive Bladder Syndrome
- Trial name
- DINKS (NCT06389838)
- Testing
- Kranus Mictera
- Where
- Germany
- Volunteers
- 194 people
- Sponsor
- Kranus Health GmbH
Urinary Bladder, Overactive
Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
The study is intended to test efficacy, safety and tolerability of two doses of Mirabegron against placebo and compare the efficacy and safety with active comparator in patients with symptoms of overactive bladder.
- Trial name
- SCORPIO (NCT00689104)
- Testing
- Mirabegron, Tolterodine
- Where
- 218 sites in Australia, Austria and 28 more
- Volunteers
- 2,336 people
- Sponsor
- Astellas Pharma Inc
Urinary Incontinence, Stress, Urinary Incontinence, Urge
Sling vs Botox for Mixed Incontinence
The primary aim is to compare the effectiveness of intradetrusor injection of 100 unit injection of Botulinum toxin A to mid-urethral sling for change in MUI symptoms 6 months following treatment.
- Trial name
- MUSA (NCT04171531)
- Testing
- Botox® injection, Mid-urethral sling
- Where
- 8 sites in United States
- Volunteers
- 150 people
- Sponsor
- NICHD Pelvic Floor Disorders Network
Urinary Incontinence
Safety and Efficacy Study of a New Treatment for Symptoms of Urinary Incontinence
The purpose of this study is to determine if a new drug treatment is effective for the treatment of symptoms of urinary incontinence.
- Trial name
- NCT01340066
- Testing
- UISH001
- Where
- 3 sites in United States
- Volunteers
- 94 people
- Sponsor
- Beech Tree Labs, Inc.
Urge Incontinence, Overactive Bladder (OAB)
A Study With Mirabegron 50 mg and 25 mg in Chinese Participants With Overactive Bladder
The purpose of this study was to evaluate the efficacy of mirabegron for the treatment of overactive bladder (OAB) in Chinese participants.
- Trial name
- NCT04562090
- Testing
- mirabegron
- Where
- 15 sites in China
- Volunteers
- 249 people
- Sponsor
- Astellas Pharma China, Inc.
Overactive Bladder
A Comparison of a New Drug to Treat Overactive Bladder vs. Placebo
A new drug for overactive bladder is compared to placebo to determine if it is safe and effective. The study lasts approximately 12 weeks.
- Trial name
- NCT00350636
- Testing
- Oxybutynin topical gel
- Where
- 63 sites in United States
- Volunteers
- 789 people
- Sponsor
- Watson Pharmaceuticals